Description

Nemifitide diTFA (INN 00835 diTFA) is a synthetic pentapeptide analog of melanocyte-inhibiting factor (MIF-1). It has shown rapid-onset antidepressant effects in preclinical models and clinical trials, achieving efficacy often within 5–7 days. Its ability to cross the blood–brain barrier enables central nervous system action. Nemifitide diTFA is synthesized under GMP conditions with high purity, reliably supporting neuroscience and psychiatric research.

Product Specifications

Mechanism of Action & Research Applications

Nemifitide diTFA acts centrally as an antidepressant, with a rapid onset of effect. Though its exact mechanism remains unclear, it may involve modulation of multiple receptor systems, including 5-HT?A antagonism and interactions with NPY?, bombesin, and melanocortin receptors at micromolar levels. Its well-documented rapid antidepressant efficacy and central penetration make it a valuable tool in neuroscience and psychiatric investigations.

Side Effects (For Reference Only)

Clinical side effect profiles are limited. However, studies have reported minimal adverse effects and an excellent safety profile, reflecting a favorable research profile. Always adhere to laboratory safety protocols.

Disclaimer

This product is intended strictly for laboratory research use only. It is not approved for human or veterinary use. Users should comply with institutional safety protocols.